Resistance to Proteasome Inhibitors in Cancer

Proteasome inhibitors and lessons learned from their mechanisms of action and resistance in human cancer.- Resistance to proteasome inhibitors in multiple myeloma.- Overcoming bortezomib resistance: a review on the second generation proteasome inhibitor carfilzomib in the treatment of multiple myeloma .- Proteasome inhibitors in the treatment of multiple myeloma and amyloidosis.- Profiling bortezomib resistance in multiple myeloma: implications in personalized pharmacotherapy.- Targeting mantle cell lymphoma with a strategy of combined proteasome and histone deacetylase inhibition.- Pre-clinical studies on the molecular basis of bortezomib resistance and modalities to overcome resistance in hematological malignancies.- Overcoming inherent resistance to proteasome inhibitors in head and neck cancer: Challenges and new approaches.- Targeting the proteasome pathway for the treatment of solid tumors.- Oxidative stress and the proteasome: mechanism and the therapeutic relevance.- Proteotoxic stress and proteasome inhibitor efficacy and resistance.- Proteasome inhibitors versus E3 ligase inhibitors for cancer therapy.- Novel ubiquitin E3 ligases as targets for cancer therapy: Focus on breast cancer associated gene 2 (BCA2).- The 26S proteasomal ATPases: structure, function, regulation and potential for cancer therapies.- Deubiquitinating enzymes as novel targets for cancer therapies